Tools to measure treatment adherence;Instrumentos de medida de adherencia al tratamiento

Anales de Medicina Interna

Volumn 24, Issue 3, 2007, Pages 138-141

  Nogués Solán, Xavier ^a,b   Sorli Redo M L ^a   Villar Garcia J ^a  

^a HOSPITAL DEL MAR   (Spain)

^b URFOA   (Spain)

Author keywords

Adherence; Measure tools; Osteoporosis; Treatment

Indexed keywords

ACENOCOUMAROL; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT;

DATA BASE; FRACTURE; HUMAN; INFORMATION PROCESSING; MICROELECTROMECHANICAL SYSTEM; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; QUESTIONNAIRE; REVIEW; VALIDATION PROCESS; ARTICLE; STATISTICS;

HUMANS; PATIENT COMPLIANCE; QUESTIONNAIRES;

EID: 34548038988     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Adherence to long-term-therapies: evidence for action. WHO report 2003.
2. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database. Menopause 1998; 5: 226-9.
3. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271-87.
4. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, et al. The natural history of medication compliance in a drug trial: Limitations of pill counts. Clin Pharmacol Ther 1989; 46: 169-76.
5. Haynes RB, Sackett DL, Gibson ES et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265-8.
6. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
7. Val Jiménez A, Amorós G, Martínez P, Ferández ML, León M. Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test Morisky y Green. Aten Primaria 1992; 10: 767-70.
8. Pineiro F, Gil V, Donis M, Orozco D, Pastor R, Merino J. Validez de 6 métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en la hipertensión arterial. Aten Primaria 1997; 19: 372-5.
9. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004; 38: 1363-8.
10. Corless IB, Kirksey KM, Kemppainen J, Nicholas PK, McGibbon C, Davis SM, et al. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS 2005; 19: 577-86.
11. Pratt RJ, Robinson N, Loveday HP, Pellowe CM, Franks PJ, Hankins M, et al. Adherence to antiretroviral therapy: appropriate use of sel-freporting in clinical practice. HIV Clin Trials 2001; 2: 146-59.
12. Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguélez R, Sacristán J, Marín F. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-56.
13. Guilera M, Fuentes M, Grifols M, Ferrer J, Badía X; OPTIMA study investigators. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 2006; 17: 664-71.
14. Márquez-Contreras E, Martell-Clarós N, Gil-Guillén V, De la Figuera-Von Wichmann M, Casado-Martínez JJ, Martín-de Pablos JL, et al. Compliance Group of the Spanish Society of Hypertension. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens 2006; 24: 169-75.
15. Buckwalter KC, Wakefield BJ, Hanna B, Lehmann J. New technology for medication adherence: Electronically managed medication dispensing system. J Gerontol Nurs 2004; 30: 5-8.
16. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102 (2A): 43-9.
17. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117-23.
18. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47: 694-702.
19. rd. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000; 15: 594-8.
20. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M; Comite Scientifique du GRIO. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 2005; 72: 26-31.
21. Reginster JY, Rabenda V. Adherence to treatment in osteoporosis influence on efficiency. Rev Med Suisse 2005; 1: 2278-81.